| Calf-Lymph Vaccine
Dryvax, a stored calf-lymph vaccine manufactured in the 1970’s by Wyeth Laboratories, is freeze dried (lyophilized) and must be reconstituted with a diluent before use.
The vaccine currently licensed will be used in 2003 to fulfill the recommendations of the national Advisory Committee on Immunization Practice (ACIP) for immunization of smallpox public health and healthcare response teams.
Dryvax is also being used ito immunize laboratory workers who require vaccination to safely conduct research activities involving vaccinia or other orthopoxviruses.
Note: Dryvax contains antibiotics and preservatives.
Appropriate history of allergies to any of the following should be obtained and may negate
vaccine administration when smallpox is not present:
| • |
Polymyxin B sulfate |
| • |
Streptomycin sulfate |
| • |
Chlortetracycline hydrochloride |
| • |
Neomycin sulfate |
If smallpox is present and the risk of contact great, the vaccine should be administered with subsequent
use of an appropriate antihistamine or other medication.
For more information on both types of vaccines, please visit the
In-depth Vaccine Information page.
|
Tissue Culture Cell Vaccine
As of October 2002, tissue culture cell vaccines are in preparation by Acambis-Baxter Laboratories.
Two cell lines were selected for propagation of vaccinia virus:
| • |
Vero monkey kidney cells |
| • |
Human fibroblast cell line (MRC5) |
Several lots of both vaccines have been
prepared and are undergoing testing. It is anticipated that one of
these vaccines will supplant calf-lymph vaccine if a more extensive
vaccination program is implemented.
|